Accelerating Biologics Discovery & Development Through Transformative Technologies & Overcoming Strategic Challenges
A concise report featuring insights from the prominent thought leaders of Biologics 2024
Exploring Innovative Approaches Throughout the CGT Development Journey
A Concise Report Featuring Insights From The Prominent Thought Leaders Of Cell UK
Unlocking the Future of Immune Cancer Therapy
A concise report featuring insights from the prominent though leaders of Immuno 2024.
Drug Discovery & Development
Antibody Discovery by Single B Cell Screening on Beacon®
On-Demand Webinar featuring Dr Amy Sheng, Technical Account Manager at Sino Biological
3D Cell Culture
In Conversation With...Stefan Przyborski, Professor, Durham University
In this video Q&A we discuss Stefan's recent work with bioengineered human tissues and the challenges to adopting 3D cell culture technologies in research.
Drug Discovery & Development
Experts Discuss Developing Oncolytic Virus Immunotherapy
Our November Immuno-Oncology Discussion Group brought together experts in the field of oncolytic virus development to discuss engineering and translational strategies of the field
3D Cell Culture
Apical-Out Organoids: A Novel Strategy to Control the Polarity of Organoids Closing
Genentech are developing several complex gastrointestinal in vitro models, including the innovative apical-out organoids.
NextGen Therapeutics
Regeneron’s New Bispecific: A Toxic Success?
Regeneron announced that their bispecific odronextamab had the highest recorded complete response rate for follicular lymphoma, but the therapeutic antibody’s safety profile has thrown up several concerns.
Dual-Action Malaria Vaccine Takes the Punch out of the Parasite
A new vaccine duo developed by scientists at George Washington University stops malaria infection and transmission, the double attack needed to eradicate the disease.
Drug Discovery & Development
What are the Key Challenges in Developing Bispecific Antibodies for Cancer Immunotherapy?
Are there too many opportunities in antibody-based immunotherapy? How do you choose your targets? How do you know when to kill a project?
Nexelis’s Collaborative Development for Optimal Clinical Assay
November’s webinar, Adaptive Laboratory Environment: Collaboration Across our Development Teams Produces Optimal Clinical Assay, discusses Nexelis’s process in recombinant protein production, optimisation, and characterisation.
Manufacturing & Bioprocessing
Q &A with Shilpi Rajoria
An interview Shilpi Rajoria, Director QC Analytical Testing at Bristol Myers Squibb.
Vaccines
Overcoming Vaccine Manufacturing Challenges
Experts from King’s College London, Janssen, and Merck Sharp & Dohme congregate to talk the future of optimised vaccine manufacturing.
3D Cell Culture
Understanding the Capabilities of 3D Bioprinting for Cell and Gene Therapy
Exploring academic perspectives on 3D bioprinting techniques for cancer and disease indication models.
Vaccines After COVID: How the Pandemic Has Changed the Vaccination Market
During the pandemic, a layperson couldn't avoid learning about vaccinations. But as the world returns to “normal”, how does this new-found focus on vaccines manifest for regulators, producers, prescribers, and the public?